Drug intelligence / Profile preview

RQ-3400

Development stage: Preclinical
Lead developer: Shanghai Lanque Biomedical
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

RQ-3400 is an mRNA-based vaccine candidate being developed by RNAcure for the prevention of shingles (herpes zoster). The vaccine is designed to deliver messenger RNA encoding a specific antigen from the varicella-zoster virus (VZV), which triggers the host's immune system to produce a protective response. This approach aims to prevent the reactivation of latent VZV, which causes shingles, particularly in older adults or immunocompromised individuals. RQ-3400 is currently in the early stages of development within RNAcure's infectious disease pipeline.

Targets

gE (VZV glycoprotein E)

Beyond the preview

Go deeper on RQ-3400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RQ-3400.